CAH · Cardinal Health Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · CAH

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$222.58B	$226.83B	$205.01B	$181.36B	$162.47B	$152.92B
Cost of Revenue	$214.41B	$219.41B	$198.12B	$174.82B	$155.69B	$146.05B
Gross Profit	$8.17B	$7.41B	$6.89B	$6.54B	$6.78B	$6.87B
R&D	-	-	-	-	-	-
SG&A	$5.38B	$5.00B	$4.83B	$4.56B	$4.53B	$4.57B
Total Operating Expenses	-	-	-	-	-	-
D&A	$790.00M	$710.00M	$692.00M	$692.00M	$783.00M	$913.00M
Operating Income	$2.27B	$1.24B	$727.00M	($596.00M)	$472.00M	($4.10B)
Interest Expense	$215.00M	$51.00M	$93.00M	$149.00M	$180.00M	$238.00M
Income Tax	$532.00M	$348.00M	$376.00M	$163.00M	($289.00M)	($79.00M)
Net Income	$1.56B	$852.00M	$261.00M	($933.00M)	$611.00M	($3.70B)
EPS - Basic	$6.48	$3.48	$1.00	($3.35)	$2.09	($12.61)
EPS - Diluted	$6.45	$3.45	$1.00	($3.35)	$2.08	($12.61)

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$3.87B	$5.13B	$4.04B	$4.72B	$3.41B	$2.77B
Accounts Receivable	$13.24B	$12.08B	$11.34B	$10.56B	$9.10B	$8.26B
Inventory	$16.83B	$14.96B	$15.94B	$15.64B	$14.59B	$13.20B
Accounts Payable	$34.71B	$31.76B	$29.81B	$27.13B	$23.70B	$21.37B
Current Assets	$36.37B	$34.88B	$33.83B	$32.94B	$31.05B	$25.94B
Total Assets	$53.12B	$45.12B	$43.42B	$43.88B	$44.45B	$40.77B
Current Liabilities	$38.90B	$35.64B	$33.71B	$30.55B	$27.62B	$23.61B
Long-term Debt	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-
Stockholders' Equity	($2.78B)	($3.21B)	($2.85B)	($709.00M)	$1.79B	$1.79B
Retained Earnings	$783.00M	($286.00M)	($534.00M)	($280.00M)	$1.21B	$1.17B

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$2.40B	$3.76B	$2.84B	$3.12B	$2.43B	$1.96B
Investing Cash Flow	($5.59B)	($1.85B)	($454.00M)	$567.00M	($378.00M)	$493.00M
Financing Cash Flow	$1.94B	($847.00M)	($3.05B)	($2.46B)	($1.32B)	($2.20B)
CapEx	$547.00M	$511.00M	$481.00M	$387.00M	$400.00M	$375.00M
Free Cash Flow	$1.85B	$3.25B	$2.36B	$2.73B	$2.03B	$1.58B

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	3.7%	3.3%	3.4%	3.6%	4.2%	4.5%
Operating margin	1.0%	0.5%	0.4%	-0.3%	0.3%	-2.7%
EBITDA margin	1.4%	0.9%	0.7%	0.1%	0.8%	-2.1%
Net margin	0.7%	0.4%	0.1%	-0.5%	0.4%	-2.4%
Free cash flow margin	0.8%	1.4%	1.2%	1.5%	1.2%	1.0%
FCF / Net income	1.19	3.82	9.03	-2.93	3.32	-0.43
R&D / Revenue	-	-	-	-	-	-
SG&A / Revenue	2.4%	2.2%	2.4%	2.5%	2.8%	3.0%
Effective tax rate	25.4%	29.0%	59.0%	-	-89.8%	-
Return on assets	2.9%	1.9%	0.6%	-2.1%	1.4%	-9.1%
Return on equity	-56.1%	-26.5%	-9.2%	131.6%	34.1%	-206.6%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	0.94	0.98	1.00	1.08	1.12	1.10
Quick ratio	0.50	0.56	0.53	0.57	0.60	0.54
Cash ratio	0.10	0.14	0.12	0.15	0.12	0.12
Leverage
Debt / Equity	-	-	-	-	-	-
Debt / Assets	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	10.6x	24.4x	7.8x	-4.0x	2.6x	-17.2x
Equity multiplier	-19.10	-14.04	-15.22	-61.89	24.82	22.79
Liabilities / Assets	-	-	-	-	-	-
Efficiency
Asset turnover	4.19	5.03	4.72	4.13	3.65	3.75
Inventory turnover	12.74	14.67	12.43	11.18	10.67	11.07
Days sales outstanding	22d	19d	20d	21d	20d	20d
Days inventory outstanding	29d	25d	29d	33d	34d	33d
Days payable outstanding	59d	53d	55d	57d	56d	53d
Cash conversion cycle	-9d	-9d	-5d	-3d	-1d	-1d
Valuation
P / E	26.0x	28.5x	94.6x	-	27.4x	-
P / B	-	-	-	-	9.4x	8.5x
P / S	0.2x	0.1x	0.1x	0.1x	0.1x	0.1x
EV / EBITDA	12.0x	9.8x	14.6x	102.8x	10.7x	-
Growth
Revenue growth (YoY)	-1.9%	10.6%	13.0%	11.6%	6.2%	5.1%
Revenue CAGR (3y)	7.1%	11.8%	10.3%	7.6%	5.9%	5.6%
Revenue CAGR (5y)	7.8%	9.3%	8.4%	6.9%	6.0%	8.3%
Gross profit growth (YoY)	10.2%	7.6%	5.3%	-3.4%	-1.3%	0.5%
Operating income growth (YoY)	83.0%	71.0%	-	-	-	-
Net income growth (YoY)	83.2%	226.4%	-	-	-	-
EPS growth (YoY)	87.0%	245.0%	-	-	-	-
EPS CAGR (3y)	-	18.4%	-	-	36.9%	-
EPS CAGR (5y)	-	-5.3%	4.3%	-	-13.6%	-
FCF growth (YoY)	-43.1%	37.9%	-13.8%	34.8%	28.0%	-33.8%
FCF CAGR (5y)	3.1%	6.3%	-0.2%	28.0%	-4.1%	-6.7%
Book value growth (YoY)	13.4%	-12.7%	-302.3%	-	0.1%	-71.7%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-06-30.

Business segments

$218.86B total

Pharmaceutical And Specialty Solutions$204.64B · 93.5%

GMPD$12.64B · 5.8%

All Other Segments$1.58B · 0.7%

Geographic

$222.66B total

US$220.99B · 99.3%

Non Us$1.67B · 0.7%

Stability scores

Piotroski F-score

FY 2025 · 9-point quality

6/9

Neutral

✓Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✓No share dilution
✓Gross margin improved
✗Asset turnover improved

Peer comparison

Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries

Company	Revenue (last FY)	Net margin	ROE
COR	$321.33B	0.5%	103.1%
MCK	$403.43B	1.2%	-219.2%
NUS	$1.49B	10.8%	19.9%
HLF	$5.04B	4.5%	-44.3%
PETQ	-	-	-

Comparing CARDINAL HEALTH INC against the 5 most active filers in the same SIC group.

Dividends

$2.04/share trailing 12 months · +1.0% YoY

Ex-date	Per share
Apr 1, 2026	$0.5110
Jan 2, 2026	$0.5110
Oct 1, 2025	$0.5110
Jul 1, 2025	$0.5110
Apr 1, 2025	$0.5060
Jan 2, 2025	$0.5060
Oct 1, 2024	$0.5060
Jul 1, 2024	$0.5060
Mar 28, 2024	$0.5010
Dec 29, 2023	$0.5010
Oct 2, 2023	$0.5010
Jun 30, 2023	$0.5010
Mar 31, 2023	$0.4960
Dec 30, 2022	$0.4960
Sep 30, 2022	$0.4960
Jun 30, 2022	$0.4960
Mar 31, 2022	$0.4910
Dec 31, 2021	$0.4910
Sep 30, 2021	$0.4910
Jun 30, 2021	$0.4910
Mar 31, 2021	$0.4860
Dec 31, 2020	$0.4860
Sep 30, 2020	$0.4860
Jun 30, 2020	$0.4860